Financials

News Ideas Discussions Technicals Forecast Seasonals

PHGE fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

PHGE has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company